(Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | (Q3)Mar 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | -1.67%5.04B | ---- | -8.04%11.17B | -9.72%8B | -9.38%5.12B | ---- | -11.71%12.14B | --8.86B | -18.70%5.65B | --2.26B |
Operating income | -1.67%5.04B | -8.04%11.17B | -9.38%5.12B | -11.71%12.14B | -18.70%5.65B | |||||
Cost of sales | 4.43%-3.12B | ---- | 0.75%-6.83B | ---- | -10.85%-3.27B | ---- | -7.95%-6.89B | ---- | 5.96%-2.95B | ---- |
Operating expenses | 4.43%-3.12B | 0.75%-6.83B | -10.85%-3.27B | -7.95%-6.89B | 5.96%-2.95B | |||||
Gross profit | 3.19%1.91B | -17.59%4.33B | -31.43%1.86B | -28.70%5.26B | -29.15%2.71B | |||||
Selling expenses | -79.49%-374.52M | ---- | -35.74%-526.24M | ---- | -18.07%-208.66M | ---- | -100.95%-387.67M | ---- | -158.85%-176.73M | ---- |
Administrative expenses | 27.19%-339.23M | ---- | 24.46%-867.15M | ---- | 20.73%-465.94M | ---- | -32.91%-1.15B | ---- | -62.01%-587.78M | ---- |
Research and development expenses | -23.65%-760.11M | ---- | -8.06%-1.48B | ---- | -1.76%-614.72M | ---- | -104.62%-1.37B | ---- | -155.70%-604.12M | ---- |
Impairment and provision | -53.58%389K | ---- | -878.88%-9.88M | ---- | -56.47%838K | ---- | 116.57%1.27M | ---- | 373.05%1.93M | ---- |
-Other impairment is provision | -53.58%389K | ---- | -878.88%-9.88M | ---- | -56.47%838K | ---- | 116.57%1.27M | ---- | 373.05%1.93M | ---- |
Special items of operating profit | 61.88%388.94M | ---- | -18.22%515.41M | ---- | -31.69%240.26M | ---- | 6.42%630.25M | ---- | 38.65%351.75M | ---- |
Operating profit | 2.84%830.07M | -34.18%1.96B | -52.26%807.15M | -52.15%2.98B | -50.34%1.69B | |||||
Financing cost | -68.60%-18.51M | ---- | 6.17%-27.19M | ---- | 25.26%-10.98M | ---- | -15.71%-28.98M | ---- | -93.83%-14.69M | ---- |
Earning before tax | 1.93%811.56M | 25.22%399.7M | -34.45%1.94B | -47.14%1.32B | -52.49%796.17M | -49.25%319.2M | -52.42%2.95B | 2.5B | -50.66%1.68B | 629M |
Tax | -62.83%-128.36M | ---- | 34.36%-291.45M | ---- | 72.94%-78.83M | ---- | 51.86%-444.01M | ---- | 43.77%-291.28M | ---- |
After-tax profit from continuing operations | -4.76%683.2M | -34.47%1.65B | -48.19%717.34M | -52.52%2.51B | -51.90%1.38B | |||||
Earning after tax | -4.76%683.2M | 12.83%339.5M | -34.47%1.65B | -43.20%1.23B | -48.19%717.34M | -42.86%300.9M | -52.52%2.51B | -47.36%2.16B | -51.90%1.38B | -55.34%526.6M |
Profit attributable to shareholders | -4.76%683.2M | -34.47%1.65B | -48.19%717.34M | -52.52%2.51B | -51.90%1.38B | |||||
Basic earnings per share | -5.17%0.112 | -35.17%0.2701 | -48.83%0.1181 | -52.95%0.4166 | -52.36%0.2308 | |||||
Diluted earnings per share | -4.47%0.1111 | -34.34%0.2667 | -48.03%0.1163 | -52.44%0.4062 | -51.91%0.2238 | |||||
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- | -- |
Auditor | -- | -- | Deloitte & Touche Tohmatsu Certified Public Accountants | -- | -- | -- | Deloitte & Touche Tohmatsu Certified Public Accountants | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
No Data